Methyl iodide → HCID 58542030、化合物
反応式
[Br:1][C:2]1[CH:25]=[CH:24][C:5]2[N:6]([C:20]([CH3:23])([CH3:22])[CH3:21])[C:7]([C:9]3[CH:14]=[CH:13][CH:12]=[CH:11][C:10]=3[C:15]3[N:19]=[CH:18][NH:17][N:16]=3)=[N:8][C:4]=2[CH:3]=1.[C:26]([O-])([O-])=O.[K+].[K+].CI>CN(C=O)C.CCOC(C)=O>[Br:1][C:2]1[CH:25]=[CH:24][C:5]2[N:6]([C:20]([CH3:22])([CH3:21])[CH3:23])[C:7]([C:9]3[CH:14]=[CH:13][CH:12]=[CH:11][C:10]=3[C:15]3[N:19]=[CH:18][N:17]([CH3:26])[N:16]=3)=[N:8][C:4]=2[CH:3]=1参加物
6
実験手順
To a vial is added 5-bromo-1-tert-butyl-2-[2-(1H-[1,2,4]triazol-3-yl)-phenyl]-1H-benzimidazole (100 mg, 0.252 mmol) in DMF (1.5 mL), followed by the addition of K2CO3 (70 mg, 0.504 mmol) and MeI (60 mg, 0.423 mmol). The reaction mixture is stirred at room temperature for 1 hour. The reaction mixture is diluted with EtOAc, washed with water, brine, dried using anhydrous Na2SO4 and filtered. The filtrate is concentrated and the residue is purified by silica gel flash column chromatography with 0-3% 7M NH3 in MeOH/CH2Cl2 as the eluent to afford 5-bromo-1-tert-butyl-2-[2-(1-methyl-1H-[1,2,4]-triazol-3-yl)-phenyl]-1H-benzimidazole (37 mg, 36%) as a light brown solid. LCMS (ESMS): m/z 410.58, 412.51 (M++1)
後処理
- washwashed with water, brine
- customdried
- filtrationfiltered
- concentrationThe filtrate is concentrated
- customthe residue is purified by silica gel flash column chromatography with 0-3% 7M NH3 in MeOH/CH2Cl2 as the eluent
出典と根拠
- ORDレコード
- ord-88d965ba7ba142a98fc1171697858537
- 出典データセット
- uspto-grants-2013_04
- 特許番号
- US08420655B2
反応ノート
読み込み中…